Nestruck A C, Pande S V, Davignon J
Atherosclerosis. 1985 Jun;55(3):353-6. doi: 10.1016/0021-9150(85)90112-1.
Oral carnitine has been reported to have a lipid-lowering effect with concomitant elevation of high density lipoprotein cholesterol (HDL-C) levels in normo- and hyperlipidemic individuals. Unexpectedly, basal carnitine concentrations were found to be abnormally high in subjects receiving a combination of probucol (1 g/day) and clofibrate (2 g/day), and who also had reduced HDL-C levels. Changes in plasma carnitine levels were found to correlate with clofibrate therapy and to be readily reversible with cessation of this drug. These increases of circulating carnitine were not accompanied by a rise in HDL-C.
据报道，口服肉碱对血脂正常和血脂异常的个体具有降血脂作用，同时可提高高密度脂蛋白胆固醇（HDL-C）水平。出乎意料的是，在接受普罗布考（1克/天）和氯贝丁酯（2克/天）联合治疗且HDL-C水平降低的受试者中，发现基础肉碱浓度异常升高。发现血浆肉碱水平的变化与氯贝丁酯治疗相关，并且在停用该药物后很容易逆转。循环肉碱的这些增加并未伴随HDL-C的升高。
